Zomedica CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Anthony K Blair, COO of Zomedica Corp., received 500,000 shares of common stock on August 5, 2026.
Karen Dehaan-Fullerton, General Counsel of Zomedica Corp., received 250,000 shares of common stock on August 5, 2026.
Russell Kevin Klass, Sr Vice President, Sales of Zomedica Corp., received 250,000 shares of common stock on August 5, 2026.
Zomedica Corp. reports a significant purchase of common stock by its Sr. Vice President, Sales, Kevin Klass.
Zomedica Corp. director Johnny D. Powers reported the acquisition of 100,000 shares of common stock on May 18, 2026, at a price of $0.103 per share.
Zomedica Corp. reports insider transactions by Sr. Vice President, Sales, Kevin Klass, involving the acquisition of common stock.
Zomedica Corp. director Johnny D. Powers reported the acquisition of 108,871 shares on May 8, 2026, and an additional 391,129 shares on May 11, 2026.
Zomedica Corp. CEO Larry C. Heaton II purchased 250,000 shares of common stock at $0.11 per share.
Director Sean Whelan received 1,975,033 stock appreciation rights at a $0.10 base price, first exercisable on 2026-11-16 and expiring on 2035-11-16.
Director Johnny D. Powers received 1,823,107 stock appreciation rights at a $0.1 base price, vesting 11/16/2026 and expiring 11/16/2035.
Director Pamela Nichols received 1,823,107 stock appreciation rights at a $0.10 exercise price, first exercisable 11/16/2026 and expiring 11/16/2035.
Director Christopher R. MacLeod received 1,823,107 stock appreciation rights exercisable from Nov. 16, 2026 and expiring Nov. 16, 2035.
Director Robert Cohen received 1,823,107 stock appreciation rights, exercisable from Nov. 16, 2026 and expiring Nov. 16, 2035 at a $0.10 base price.
Zomedica Corp. disclosed a grant of 1,975,033 stock appreciation rights to Director Rodney J. Williams, exercisable starting 11/16/2026 and expiring 11/16/2035.
Zomedica awarded Director Jeffrey M. Rowe 2,126,959 stock appreciation rights at a $0.10 exercise price, exercisable from November 16, 2026 and expiring November 16, 2035.
Form 4: Zomedica SVP Buys 150,000 Shares
Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, purchased 150,000 shares of common stock at $0.097 per share.
Zomedica's Senior Vice President of Sales, Russell Kevin Klass, purchased 120,000 shares of common stock, increasing his beneficial ownership.
Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, purchased 5,000 shares of common stock at $0.095 per share in a pre-planned transaction.
Form 4: Zomedica SVP Buys 253,007 Shares
Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, acquired 253,007 shares of common stock at $0.08 per share.
Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, significantly increased his direct ownership of common stock through multiple purchases at $0.04 per share in August 2025.
Form 4: Zomedica SVP Boosts Stake
Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, increased his direct beneficial ownership by 500,000 shares through open market purchases.
Form 4: Zomedica SVP Buys 500,000 Shares
Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, acquired 500,000 shares of common stock, increasing his beneficial ownership.
Zomedica Corp.'s Chief Operating Officer, Anthony K. Blair, has been granted 750,000 options to purchase common stock at an exercise price of $0.05 per share, vesting over four years.
Russell Kevin Klass, Senior Vice President of Sales at Zomedica Corp., has been granted 500,000 options to purchase common stock with an exercise price of $0.05 per share.
Zomedica Corp. CEO and Director Larry C. Heaton II was granted 4 million stock options with an exercise price of $0.05, vesting over four years.
Zomedica Corp.'s General Counsel, Karen DeHaan-Fullerton, was granted 500,000 options to purchase common stock at an exercise price of $0.05 per share, vesting over four years.
Zomedica Corp.'s COO, Anthony K. Blair, reports the acquisition of 100,000 shares of common stock through open market purchases.
Karen DeHaan-Fullerton, General Counsel/Corporate Secretary of Zomedica Corp., reports acquiring 104,300 shares of common stock at $0.048 per share on May 19, 2025.
Director Johnny D. Powers of Zomedica Corp. reports the acquisition of 500,000 shares of common stock at $0.046 per share on May 19, 2025.
Jeffrey M. Rowe, a director of Zomedica Corp., amended his Form 4 filing to accurately reflect share ownership held by the Jeffrey M. Rowe Living Trust.